Isis Pharmaceuticals Ends 2012 with an Antisense Cancer Alliance with AstraZeneca
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 12 (Table of Contents)
Published: 31 Dec-2012
DOI: 10.3833/pdr.v2012.i12.1864 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
AstraZeneca has become the latest big pharma company to access Isis Pharmaceuticals’ antisense technology platform as part of a strategic alliance to discover and develop next- generation antisense therapeutics against five cancer targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS